radium-223-dichloride

Drug Overview

Radium-223 dichloride is a targeted alpha-emitting radiopharmaceutical that selectively accumulates in areas of high bone turnover, such as osteoblastic metastases common in metastatic castration-resistant prostate cancer (mCRPC), delivering cytotoxic radiation directly to cancer cells while minimizing exposure to surrounding healthy tissues due to its short-range alpha particles. As a “targeted alpha therapy,” it represents a unique class of bone-seeking agents that provide both palliative and survival benefits in advanced prostate cancer with symptomatic skeletal involvement. ​radium-223-dichloride

• Generic name: Radium-223 dichloride
• US Brand names: Xofigo
• Drug Class: Targeted alpha therapy; calcium mimetic radiopharmaceutical (high-linear energy transfer [LET] alpha emitter with bone tropism)
• Route of Administration: Intravenous injection
• FDA Approval Status: FDA-approved in May 2013 for adults with mCRPC, symptomatic bone metastases, and no known visceral metastases; subsequent approvals in Europe, Japan, and other regions for similar bone-dominant CRPC indications
  
  Discover vital facts about zolbetuximab-clzb. Read our best, proven guide to learn safe uses, critical benefits, and top care strategies.radium-223-dichloride

What Is It and How Does It Work? (Mechanism of Action)

Radium-223 dichloride (²²³RaCl₂) chemically mimics ionic calcium (Ra²⁺), preferentially incorporating into hydroxyapatite matrix in zones of active osteoblastic bone formation surrounding metastatic lesions. Its decay chain emits high-energy alpha particles with a tissue range of 2-10 cells, inducing irreparable double-strand DNA breaks preferentially in tumor cells and supportive bone microenvironment components.

• Calcium mimetic incorporation into pathological bone matrix
  • Ra²⁺ ions substitute for Ca²⁺ during hydroxyapatite crystallization in woven bone produced by tumor-stimulated osteoblasts, achieving tumor-to-bone uptake ratios of 5-10:1 due to elevated alkaline phosphatase and osteocalcin in metastatic sites.​
  • Physical half-life of 11.4 days supports 6 sequential alpha decays (²²³Ra → ²¹⁹Rn → ²¹⁵Po → etc.), releasing 95% energy as alpha particles with progeny recoil distances <100 μm, confining damage locally.​
• High-LET alpha particle-induced irreparable DNA damage
  • Alpha emissions (5.6-7.5 MeV) deposit energy at 50-230 keV/μm (high LET), producing clustered/complex double-strand breaks (DSBs) and non-DSB oxidative lesions that overwhelm DNA repair pathways (NHEJ, HR, alt-NHEJ).​
  • Only 1-4 alpha traversals suffice for cell lethality regardless of cell cycle phase, contrasting beta-emitters requiring thousands of hits; induces persistent γH2AX foci and mitotic catastrophe.
• Dual cytotoxicity to tumor cells and bone microenvironment
  • Direct killing of prostate cancer cells within 2-10 cell diameters; collateral ablation of osteoblasts, osteoclasts, and stromal cells disrupts vicious tumor-bone cycles (PTHrP → RANKL/OPG imbalance → IL-6/IGF-1 feedback).​
  • Normalizes bone turnover markers (BSAP, CTX, NTX), reducing pathological fractures and SREs.
• Immunogenic cell death and abscopal effects
  • Alpha-induced endoplasmic reticulum stress triggers immunogenic cell death (ICD) with calreticulin exposure, ATP release, and HMGB1, activating STING/TLR pathways for dendritic cell maturation and adaptive antitumor immunity in bone marrow niche.

FDA-Approved Clinical Indications

Strictly limited to bone-dominant mCRPC without visceral involvement, distinguishing it from systemic chemotherapies.

• Oncological uses
  • Treatment of adults with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases (e.g., ECOG PS 0-2, significant skeletal pain), and no known visceral metastases on imaging.​
• Non-oncological uses (if any)
  • None FDA-approved; investigational in other osteoblastic malignancies (e.g., breast cancer bone mets).

Dosage and Administration Protocols

Fixed weight-based dosing at 55 kBq/kg IV q4 weeks ×6 cycles; rapid 1-minute push injection via peripheral IV with immediate saline flush. Bone-specific uptake precludes routine renal/hepatic dose modifications.​

Clinical Efficacy and Research Results

ALSYMPCA phase III (n=921; 2013 primary, 2020-2025 follow-ups) confirmed unprecedented survival benefit among bone agents.

• ALSYMPCA: Median OS 14.9 vs 11.3 months (HR 0.70, 95% CI 0.58-0.83, p<0.001); 30% mortality risk reduction; chemotherapy-naïve subgroup HR 0.67.
• SREs: Median time to first SRE 25.1 vs 16.9 months (HR 0.443); 38% fewer total SREs; pain response 45-58%.
• 2020-2025 real-world/PEACE-3: OS 12-18 months; PSA50 ~16%; alkaline phosphatase normalization 40-60%; PSMA-PET selected patients show prolonged bone PFS.
• No visceral disease mandatory; abiraterone combinations increase fracture risk without additive survival.

Safety Profile and Side Effects

Black Box Warning

• Bone marrow suppression leading to MDS/AML: Cumulative incidence ~2%; monitor serial CBCs; secondary malignancy risk from alpha radiation.​
• Radiation exposure precautions: Alpha emitter; patient restrictions on close contact (sleeping separately, no young children/pregnant women for 5-7 days post-dose).

Common side effects (>10%)

• GI: Nausea (35%), diarrhea (24%), vomiting (18%), constipation (17%); mild, self-limited.
• Hematologic: Anemia (31%), thrombocytopenia (12%), neutropenia (5%); nadir days 14-21.
• Management: Prophylactic antiemetics (ondansetron 8 mg); dietary modifications; hold/delay for grade 3-4 cytopenias; RBC/platelet transfusion PRN.

Serious adverse events

• MDS/AML (1-2%): Persistent cytopenias, fatigue, infections, circulating blasts beyond 8 weeks; urgent hematology referral, bone marrow biopsy.
• Pathologic fractures (secondary to turnover suppression): New/worsening bone pain; DEXA, bisphosphonates/denosumab post-therapy.
• Spinal cord compression (disease progression): Emergent high-dose dexamethasone, RT/surgery.

Connection to Stem Cell and Regenerative Medicine (Research Areas)

Radium-223 disrupts bone marrow microenvironment, complementing hematopoietic stem cell transplantation preconditioning; phase I/II trials explore combinations with CAR-T cells and PD-1 inhibitors leveraging alpha-induced immunogenic cell death for enhanced antitumor immunity.

Patient Management and Practical Recommendations

Nuclear medicine/medical oncology/urology multidisciplinary approach with radiation safety officer oversight mandatory.

• Pre-treatment tests: CBC/differential/platelets, PSA, total ALP, pain VAS score (≥2/10), bone scan/NaF-PET/CT (confirm no visceral/lymph node >3 cm), CrCl, hemoglobin ≥10 g/dL, ECOG 0-2, life expectancy >6 months.
• Precautions during treatment: Weekly CBCs cycles 1-2 (q2 weeks thereafter); radiation hygiene (separate sleeping, no child contact <5 days, double toilet flush 1 week); contraception (semen analysis post-therapy); avoid UTI.
• Do’s
  • Hydrate 2-3 L/day pre/post-injection to aid renal clearance.
  • Maintain voiding hygiene (frequent urination, sitz baths if needed).
  • Adhere to 6-injection calendar q4 weeks for full benefit.
• Don’ts
  • Administer >6 cycles, with visceral mets, or active cord compression.
  • Ignore new cytopenias, worsening bone pain, or fevers.
  • Close physical contact with children/pregnant women for 5-7 days post-dose.

Legal Disclaimer

This content provides general educational information only and does not constitute medical advice, diagnosis, or treatment recommendations. Patients and clinicians must consult qualified specialists, adhere to current prescribing information, radiation safety regulations, and individual patient factors.